Literature DB >> 9681662

Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.

C De Santi1, P C Giulianotti, A Pietrabissa, F Mosca, G M Pacifici.   

Abstract

OBJECTIVE: The aim of this investigation was to study the variation of catechol-O-methyltransferase (COMT) activity in the human liver, duodenal mucosa and renal cortex, and to investigate the inhibition of COMT by entacapone and tolcapone. This study included 87 samples of human liver, 94 samples of the duodenum and 72 samples of the renal cortex.
RESULTS: The activity of COMT was measured with 3,4-dihydroxybenzoic acid (242 micromol x l(-1)), the methyl acceptor substrate, and adenosyl-L-methionine (44 micromol x l(-1)), the methyl donor substrate. The hepatic activity of COMT activity was significantly higher in men than in women, whereas it was not sex-dependent in the duodenum or renal cortex. The activity of COMT varied 4.4-fold in the liver of men, 2.6-fold in the duodenum and 5.3-fold in the renal cortex. The median estimates of COMT activity were 577, 499, 103 and 159 pmol x min(-1) x mg(-1) in the liver of men and women, in the duodenum and in the renal cortex, respectively.
CONCLUSION: Entacapone and tolcapone were powerful inhibitors of COMT and their IC50 estimates were 151 and 773 nM (P = 0.008), respectively, in the liver; consistent results were obtained with the other tissues.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681662     DOI: 10.1007/s002280050448

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

Review 1.  Entacapone. A review of its use in Parkinson's disease.

Authors:  K J Holm; C M Spencer
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

2.  Dopamine is metabolised by different enzymes along the rat nephron.

Authors:  Fernando R Ibarra; Inés Armando; Susana Nowicki; Andrea Carranza; Verónica De Luca Sarobe; Elvira E Arrizurieta; Marta Barontini
Journal:  Pflugers Arch       Date:  2005-04-30       Impact factor: 3.657

Review 3.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Tolcapone: a review of its use in the management of Parkinson's disease.

Authors:  Gillian M Keating; Katherine A Lyseng-Williamson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice.

Authors:  M Käenmäki; A Tammimäki; J A Garcia-Horsman; T Myöhänen; N Schendzielorz; M Karayiorgou; J A Gogos; P T Männistö
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

6.  A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods.

Authors:  Anu J Tervo; Tommi H Nyrönen; Toni Rönkkö; Antti Poso
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

7.  Identification of immune-relevant genes from atlantic salmon using suppression subtractive hybridization.

Authors:  S C M Tsoi; K V Ewart; S Penny; K Melville; R S Liebscher; L L Brown; S E Douglas
Journal:  Mar Biotechnol (NY)       Date:  2004-04-29       Impact factor: 3.619

Review 8.  Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension.

Authors:  Stevan P Tofovic; Edwin K Jackson
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

Review 9.  Utility of tolcapone in fluctuating Parkinson's disease.

Authors:  Fabrizio Stocchi; Maria Francesca De Pandis
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

10.  A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.

Authors:  David E Gordon; Gwendolyn M Jang; Mehdi Bouhaddou; Jiewei Xu; Kirsten Obernier; Matthew J O'Meara; Jeffrey Z Guo; Danielle L Swaney; Tia A Tummino; Ruth Hüttenhain; Robyn M Kaake; Alicia L Richards; Beril Tutuncuoglu; Helene Foussard; Jyoti Batra; Kelsey Haas; Maya Modak; Minkyu Kim; Paige Haas; Benjamin J Polacco; Hannes Braberg; Jacqueline M Fabius; Manon Eckhardt; Margaret Soucheray; Melanie J Bennett; Merve Cakir; Michael J McGregor; Qiongyu Li; Zun Zar Chi Naing; Yuan Zhou; Shiming Peng; Ilsa T Kirby; James E Melnyk; John S Chorba; Kevin Lou; Shizhong A Dai; Wenqi Shen; Ying Shi; Ziyang Zhang; Inigo Barrio-Hernandez; Danish Memon; Claudia Hernandez-Armenta; Christopher J P Mathy; Tina Perica; Kala B Pilla; Sai J Ganesan; Daniel J Saltzberg; Rakesh Ramachandran; Xi Liu; Sara B Rosenthal; Lorenzo Calviello; Srivats Venkataramanan; Yizhu Lin; Stephanie A Wankowicz; Markus Bohn; Raphael Trenker; Janet M Young; Devin Cavero; Joe Hiatt; Theo Roth; Ujjwal Rathore; Advait Subramanian; Julia Noack; Mathieu Hubert; Ferdinand Roesch; Thomas Vallet; Björn Meyer; Kris M White; Lisa Miorin; David Agard; Michael Emerman; Davide Ruggero; Adolfo García-Sastre; Natalia Jura; Mark von Zastrow; Jack Taunton; Olivier Schwartz; Marco Vignuzzi; Christophe d'Enfert; Shaeri Mukherjee; Matt Jacobson; Harmit S Malik; Danica G Fujimori; Trey Ideker; Charles S Craik; Stephen Floor; James S Fraser; John Gross; Andrej Sali; Tanja Kortemme; Pedro Beltrao; Kevan Shokat; Brian K Shoichet; Nevan J Krogan
Journal:  bioRxiv       Date:  2020-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.